References
- GLOBOCAN. 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx [Last accessed 6 May 2015]
- WHO Global Burden of Disease. 2004. Available at: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/. [Last accessed 12 March 2015]
- Transparency Committee opinion: vinorelbine soft capsules. 29 April 2009. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-05/navelbine_-_ct-6287.pdf. [Last accessed 12 March 2015]
- Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value in Health 2000;3:22-30
- Cardoso F, Costa A, Norton L, et al.; European School of Oncology; European Society of Medical Oncology. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014;23:489-502
- Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 2005;4:915-28
- Allen JM. Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care 2010;16:697-704
- Burge F, Lawson B, Johnston G. Trends in the place of death of cancer patients. CMAJ 2003;168:265-70
- Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ 2004;170:1795-801
- Lidgren M, Wilking N, Jönsson B, Rehnberg C. Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care 2007;23:223-31
- Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15
- Catania C, Didier F, Leon ME, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Canc Res Treat 2005;92:265-72
- Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008;62:85-91
- Taylor H, Burcombe R, Hill S, et al. Assessing the impact on staff resource and patient waiting time of a switch from I.V. to oral chemotherapy: time and motion model for HTAS. Proc NCRI Cancer Conference 2005;abst. P435
- James RD, Barni S, Fischer von Weikersthal L, et al. Improving chemotherapy capacity by switching from IV to oral vinorelbine. Eur J Oncol Pharm 2010;4:14-18
- Delgado J, Febrer L, Nieves D, et al. Cost-reduction analysis for oral versus intravenous fludarabine (Beneflur) in Spain. Farm Hosp 2009;33:240-6
- Lewden-Bernadac B, Courant-Menanteau M, Perrocheau G, et al. Chimiothérapie à domicile et réseau ville-hôpital: expérience du réseau Onco Pays-de-la-Loire Bulletin du Cancer 2008;95:543-9